Cannabis is not a recommended treatment for sleep apnea. Small trials found that dronabinol, a prescription synthetic THC, reduced breathing interruptions in some people with obstructive sleep apnea (OSA), but the American Academy of Sleep Medicine says medical cannabis and its synthetic extracts should not be used for OSA because the evidence on effectiveness and safety is insufficient. CPAP and other proven therapies remain the standard.
Obstructive sleep apnea happens when the airway repeatedly narrows or closes during sleep, cutting off breathing for seconds at a time. Untreated, it causes loud snoring, daytime sleepiness and higher risks of high blood pressure, heart disease and car crashes. Because many people find CPAP masks hard to tolerate, the idea of a pill or a gummy that could help has drawn real interest. Here is what the research shows as of October 2026.
Cannabis and Sleep Apnea: Evidence at a Glance
| Claim | Evidence level | Source |
|---|---|---|
| THC stabilizes breathing during sleep in rats | Animal study | Carley et al. 2002 |
| Dronabinol lowers the apnea-hypopnea index (AHI) in OSA | Limited (one pilot study, one 73-person RCT) | PACE trial 2018 |
| Cannabinoids improve short-term sleep outcomes in people with OSA | Moderate | National Academies 2017 |
| Dronabinol improves oxygen levels at night | Not shown | PACE trial 2018 |
| Medical cannabis should be used to treat OSA | No; sleep specialists advise against it | AASM 2018 |
| Dispensary cannabis helps sleep apnea | Not studied | AASM 2018 |
Where the Idea Came From
Researchers at the University of Illinois at Chicago noticed that serotonin, acting on nerves outside the brain, can make sleep apnea worse, and that cannabinoids can block some of serotonin’s effects on those nerves. In a 2002 study, they recorded the sleep of 11 rats and found that THC cut the apnea index by 42% in non-REM sleep and 58% in REM sleep, and blocked serotonin-induced worsening of apnea (Carley et al., Sleep). Rats do not have the same airway anatomy as people, so the next step was human testing.
What Human Trials Show
Pilot study, 2013
The same Chicago group gave dronabinol to 17 adults with moderate to severe OSA for three weeks, raising the dose from 2.5 mg to 10 mg a day. Breathing interruptions fell by an average of about 14 per hour, and there were no serious side effects. There was no placebo group, so the result could not prove dronabinol caused the change (Prasad et al., Frontiers in Psychiatry).
The PACE trial, 2018
The first placebo-controlled trial randomized 73 adults with moderate or severe OSA to placebo, 2.5 mg of dronabinol or 10 mg of dronabinol, taken an hour before bed for up to six weeks (Carley et al., Sleep). Compared with placebo:
- Dronabinol reduced the apnea-hypopnea index by about 11 events per hour at 2.5 mg and 13 per hour at 10 mg. The average participant started at about 26 events per hour.
- At 10 mg, self-reported daytime sleepiness improved modestly.
- Overnight oxygen levels, overall sleep structure and an objective test of staying awake did not change.
- Side effects and adherence were similar across groups.
The authors called the results promising and said larger trials were needed. To put the numbers in context: a drop of 13 from a starting average of 26 still leaves an average person with sleep apnea, just less of it, and the trial lasted only six weeks.
Combination research, 2025
Researchers have since tested dronabinol combined with acetazolamide, a drug that affects breathing control. A 2025 analysis of a randomized trial looked at which underlying causes of OSA the combination changed, finding effects on breathing control and airway collapsibility depending on dose (Thomson et al., Sleep Medicine). This is early-stage drug development, not an approved therapy.
What Sleep Specialists Say
In a 2018 position statement, the American Academy of Sleep Medicine said medical cannabis and its synthetic extracts should not be used to treat OSA because of unreliable delivery methods and insufficient evidence of effectiveness, tolerability and safety. It noted that dronabinol is not FDA-approved for OSA, that other forms of medical cannabis have not been studied in OSA, and that the makeup of medical cannabis varies widely. The academy also urged states to remove OSA from lists of qualifying conditions for medical cannabis programs.
The National Academies did find moderate evidence that cannabinoids improve short-term sleep outcomes in people with sleep disturbances tied to OSA, fibromyalgia, chronic pain and MS. Short-term sleep quality is not the same as fixing the airway problem behind OSA.
Dronabinol vs Dispensary Cannabis
Every positive human result came from dronabinol, a capsule with a precise dose of synthetic THC. Smoked, vaped or edible cannabis from a dispensary has never been tested for sleep apnea. Smoking also irritates the airways, which is a poor fit for a breathing disorder. People with insomnia sometimes use cannabis to fall asleep, but feeling sleepier is not the same as breathing better during sleep. Someone with untreated OSA who sleeps more deeply may not notice how often they stop breathing.
Risks and Side Effects
- Untreated apnea: the biggest risk is using cannabis instead of effective treatment, leaving heart and stroke risks unaddressed.
- Drowsiness: the AASM noted somnolence in most patients in early dronabinol studies, which adds to the daytime sleepiness OSA already causes. Drowsy driving is dangerous.
- Tolerance and withdrawal: nightly THC use builds tolerance, and stopping often causes poor sleep and vivid dreams for a period.
- Mood and anxiety: THC can cause anxiety or paranoia in some people.
- Dependence: nightly use can lead to cannabis use disorder.
- Interactions: cannabis adds to the effects of sedatives, sleep aids and alcohol, all of which can worsen breathing during sleep.
Talk to Your Doctor
If you snore loudly, stop breathing during sleep or are sleepy during the day, ask for a sleep evaluation; a home or lab sleep test can confirm OSA. If CPAP has not worked for you, ask about other options, such as mask changes, oral appliances, positional therapy, weight-loss treatment, surgery or nerve stimulation devices. If you use cannabis for sleep, tell your sleep doctor so it can be factored into testing and treatment.
Legal Status
Dronabinol is FDA-approved for other conditions, such as chemotherapy nausea, and any use for OSA would be off-label. A few states have listed OSA as a qualifying condition for medical cannabis, against the AASM’s advice. Adults 21 and older can buy cannabis in adult-use states such as Washington and Oregon. Cannabis remains illegal federally; see our federal law guide.
Cannabis and Sleep Apnea FAQ
Does marijuana help sleep apnea?
There is no evidence that dispensary cannabis helps. Prescription dronabinol modestly reduced breathing interruptions in small trials, but sleep specialists do not recommend it.
Can I use cannabis instead of CPAP?
No. No cannabis product has been shown to replace CPAP or other proven OSA treatments, and the AASM advises against using cannabis for OSA.
Does smoking weed make sleep apnea worse?
Smoking cannabis has not been studied specifically in OSA, but smoke irritates the airways, and sedating substances can worsen breathing during sleep. It is best avoided if you have OSA.
What is dronabinol?
Dronabinol is a synthetic form of THC sold as a prescription capsule. It is FDA-approved for chemotherapy nausea and appetite loss in AIDS, not for sleep apnea.
Is CBD good for sleep apnea?
CBD has not been tested for OSA. The only human trials used dronabinol, which is THC.
Related reading: cannabis and MS, cannabis and fibromyalgia, and more studies in our cannabis research section.
For adults 21+ in legal states. General information, not medical advice. Talk to a doctor before using cannabis for a health condition.